Monash IVF Consortium Lifts Takeover Bid to $0.90 With Hard April Deadline

A consortium comprising Genesis Capital and Soul Patts has submitted a revised non-binding indicative proposal to acquire Monash IVF Group at $0.90 per share cash, representing a 12.5% increase from the $0.80 per share offer rejected by the Board in November 2025. The proposal carries a deadline of close of business Tuesday, 21 April 2026, with the consortium stating this represents their highest offer absent competing interest.

The revised proposal follows the Board’s rejection of the original approach four months earlier, which it described as opportunistic. The consortium, which holds approximately 19.6% of Monash IVF shares as at November 2025, has explicitly stated the $0.90 per share figure represents the maximum amount it is prepared to offer unless a competing proposal emerges for all or a material part of the company.

Consortium lifts Monash IVF takeover bid to $0.90 per share

The revised non-binding proposal from Genesis Capital and Soul Patts marks a material uplift from the consortium’s initial approach. The 12.5% price increase to $0.90 per share cash comes after the Monash IVF Board unanimously rejected the $0.80 per share proposal in late 2025.

The consortium has declared this is their best and final offer in the absence of competitive tension. The proposal expires at close of business on 21 April 2026, creating a compressed timeline for the Board’s assessment and response.

While the indicative nature of the proposal means shareholders face no immediate decision, the explicit pricing ceiling and hard deadline introduce urgency into the Board’s deliberations.

The offer structure remains a proposed scheme of arrangement, requiring shareholder vote and court approval if it progresses to a binding offer. The consortium’s near-20% stake positions it as a substantial shareholder with influence over any alternative transaction.

What is a scheme of arrangement and why does it matter?

A scheme of arrangement is a court-supervised process under which a company and its shareholders agree to a fundamental restructuring or acquisition. Unlike a traditional takeover bid where shareholders tender shares individually, schemes require collective approval through a shareholder vote.

For a scheme to succeed, it must receive approval from 75% of votes cast and a majority of shareholders voting. The court must also sanction the scheme after confirming the process has been fair and proper.

Acquirers typically prefer schemes because they deliver certainty of outcome and allow the buyer to acquire 100% ownership once thresholds are met, avoiding a minority shareholder overhang.

For Monash IVF shareholders, understanding the scheme process clarifies what approval hurdles would need to be cleared if the consortium formalises its proposal. The 75% voting threshold is materially higher than a simple majority, requiring broad shareholder support for any transaction to proceed.

Conditions attached to the revised proposal

The consortium has attached four key conditions to proceeding with the proposal:

• Four-week exclusive due diligence period with no fiduciary exceptions
• Transaction documentation on customary terms including no material adverse change condition
• Unanimous Monash IVF Board recommendation
• Final internal approval from consortium members

The exclusivity demand without fiduciary carve-outs represents a significant ask. A fiduciary exception typically allows a board to engage with superior competing proposals during an exclusivity period. The absence of this provision would prevent the Board from entertaining alternative offers during the four-week window, potentially limiting competitive tension.

The requirement for unanimous Board recommendation sets a high bar for internal alignment before the consortium proceeds. The condition that consortium members still require final internal approval before any binding offer underscores the non-binding nature of the current proposal.

Consortium’s existing stake and Board response

The consortium held approximately 19.6% of Monash IVF shares as at November 2025, providing it with a blocking stake that gives significant influence over any alternative transaction. This substantial position demonstrates serious intent while creating complications for competing bidders.

The Board is currently assessing the proposal with its financial adviser Macquarie Capital and legal adviser Clayton Utz. Shareholders have been explicitly advised that no action is required at this stage. The company has noted there is no certainty discussions will result in a transaction.

The Board’s assessment will need to weigh the 12.5% premium to the rejected offer against the proposal’s conditional nature, the exclusivity demands, and potential alternative value creation pathways for shareholders.

What comes next for Monash IVF shareholders

The Board faces a compressed timeline to assess the proposal before the 21 April 2026 deadline. The likely process involves evaluating the offer price against the company’s intrinsic value, considering the attached conditions, and determining whether to engage in exclusive discussions or reject the approach.

If the Board engages with the consortium, exclusive due diligence would commence. If rejected, the consortium may either increase its offer, walk away, or potentially seek to exercise influence through its 19.6% stake. The company has committed to informing shareholders of material developments as required under continuous disclosure obligations.

The non-binding nature of the proposal means shareholders should monitor announcements closely without taking action at this stage. The Board’s response before the stated deadline will provide clarity on whether formal transaction discussions will proceed.

Shareholder Action

Shareholders do not need to take any action in relation to the Proposal.

The timeline is compressed, with the Board’s assessment and response required before close of business Tuesday, 21 April 2026. Material developments will be announced as required under continuous disclosure rules.

Want Healthcare M&A News Before the Market Moves?

Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive takeover bids, consortium proposals and merger updates the moment they hit the market.